Preview

User

Not a user? Register with this site Forgot your password?

Tuberculosis and Lung Diseases

Advanced search

Treatment Results in Patients with Drug Resistant Tuberculosis (MDR, pre-XDR, XDR) and HIV Infection in Stavropol Region

https://doi.org/10.58838/2075-1230-2024-102-3-64-70

Abstract

The objective: to compare treatment effectiveness of drug resistant tuberculosis (MDR, pre-XDR, XDR) depending on the HIV status of patients in Stavropol Region from 2019 to 2022.

Subjects and Methods. In a retrospective study, chemotherapy outcomes for pulmonary tuberculosis (TB) were evaluated with distribution by treatment regimens for MDR, pre-XDR, and XDR in 100 patients with drug resistant tuberculosis (MDR, pre-XDR, XDR and HIV infection (DR TB/HIV Group ) and 707 patients with drug resistant tuberculosis (MDR, pre-XDR, and XDR) (and negative HIV status (DR TB Group). The immune status of patients in DR TB/HIV Group and its impact on the effectiveness of tuberculosis treatment were analyzed.

Results. Effective treatment (definitions are given according to the Guidelines) was statistically significantly more frequently registered in DR TB Group versus DR TB/HIV Group (59% and 48%, respectively, p<0.05). Treatment failure was statistically significantly more frequently registered in patients in DR TB/HIV Group versus DR TB Group (42% and 26%, respectively, p<0.05). In DR TB/HIV Group, the lowest effectiveness (33%) of tuberculosis treatment was noted in the patients with CD4 count below 200 cells/µL. Among those died, the median time to death from the start of tuberculosis treatment was 12 months in DR TB Group, 8 months in DR TB/HIV Group, and 4 months in the subgroup of patients with CD4 count below 100 cells/µL.

About the Authors

N. A. Sosova
Stavropol Regional Clinical TB Dispensary
Russian Federation

Natalia A. Sosova, Head of Respiratory Diseases Department no. 1

56 Dostoevskiy St., Stavropol, 355019 

Phone: +7 (865) 28-79-31


T. A. Zadremaylova
Stavropol Regional Clinical TB Dispensary
Russian Federation

Tatyana A. Zadremaylova, Candidate of Medical Sciences, Deputy Head Physician for Medical Activities

56 Dostoevskiy St., Stavropol, 355019

Phone: + 7 (865) 28-83-61  


N. M. Konovalova
Stavropol Regional Clinical TB Dispensary
Russian Federation

Natalia M. Konovalova, Deputy Head Physician for Reporting and Statistics

56 Dostoevskiy St., Stavropol, 355019

Phone: +7 (865) 28-75-34


A. V. Abramchenko
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation

Anna V. Abramchenko, Junior Researcher of Department of Differential Diagnosis and Treatment of Tuberculosis and Concurrent Infections

4 Dostoevsky St., Moscow, 127473 

Phone: +7 (495) 544-90-17


M. I. Romanova
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation

Maria I. Romanova, Junior Researcher of Department of Differential Diagnosis and Treatment of Tuberculosis and Concurrent Infections

4 Dostoevsky St., Moscow, 127473

Phone: +7 (903) 537- 01-36


A. I. Gayda
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation

Anastasiya I. Gayda, Candidate of Medical Sciences, Senior Researcher of Department of Differential Diagnosis and Treatment of Tuberculosis and Concurrent Infections

4 Dostoevsky St., Moscow, 127473

Phone: +7 (911) 557- 04-35


A. G. Samoylova
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation

Anastasiya G. Samoylova, Doctor of Medical Sciences, Deputy Director for Research

4 Dostoevsky St., Moscow, 127473

Phone: +7 (495) 681-11-66


References

1. Balasanyants G.S. Experience of using bedaquiline in the multimodality therapy of tuberculosis patients with concurrent HIV infection. Tuberculosis and Lung Diseases, 2017, vol. 95, no. 9, pp. 49-54. (In Russ.) https:// doi.org/10.21292/2075-1230-2017-95-9-49-54

2. Vasilyeva I.A., Sterlikov S.A., Testov V.V., Mikhaylova Yu.V., Golubev N.A., Kucheryavaya D.A., Gordina A.V., Ponomarev S.B. Resursy i deyatelnost protivotuberkuleznykh organizatsiy Rossiyskoy Federatsii v 2021-2022 gg. (statisticheskiye materialy). [Resources and activities of TB units in the Russian Federation in 2021-2022. (Statistic materials)]. Moscow, RIO TSNIIOIZ Publ., 2023, 92 p.

3. Vasilyeva I.A., Testov V.V., Sterlikov S.A. Tuberculosis situation in the years of the COVID-19 pandemic – 2020-2021. Tuberculosis and Lung Diseases, 2022, vol. 100, no. 3, pp. 6-12. (In Russ.) https://doi.org/10.21292/2075-1230-2022-100-3-6-12

4. VICH-infektsiya u vzroslykh. Klinicheskie rekomendatsii. [HIV infection in adults. Guidelines]. Approved in 2020. Valid till 2022, 114 p.

5. WHO. Global Tuberculosis Report for 2023. Geneva, World Health Organisation, 2023г.

6. Edict no. 50 by RF MoH as of February 13, 2004 On Introduction of Registration and Reporting Documents for Tuberculosis Monitoring. 35 p. (In Russ.)

7. Edict no. 109 by RF MoH as of March 21, 2003 On Improvement of TB Control Measures in the Russian Federation. RF MoH, 234 p. (In Russ.)

8. Stavitskaya N.V., Felker I.G., Zhukova E.M., Tlif A.I., Doctorova N.P., Kudlay D.A. The multivariate analysis of the results of bedaquiline use in the therapy of MDR/XDR pulmonary tuberculosis. Tuberculosis and Lung Diseases, 2020, vol. 98, no. 7, pp. 56-62. (In Russ.) https:// doi.org/10.21292/2075-1230-2020-98-7-56-62

9. Central Research Institute of Epidemiology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor). Available: https://www.hivrussia.info/wp-content/uploads/2022/03/Spravka-VICH-v-Rossii-na-31.12.2021-g.. pdf Accessed November 07, 2023

10. YUNEYDS. Informatsionnyy byulleten 2023 Globalnaya statistika po VICH. [UNAIDS. Global HIV & AIDS statistics — Fact sheet for 2022]. Available: https://www.unaids.org/sites/defauit/files/media_asset/UNAIDS_FactSheet_ru.pdf Accessed November 07, 2023

11. Bayowa J.R., Kalyango J.N., Baluku J.B., Katuramu R., Ssendikwanawa E., Zalwango J.F., Akunzirwe R., Nanyonga S.M., Amutuhaire J.S., Muganga R.K., Cherop A. Mortality rate and associated factors among patients co-infected with drug resistant tuberculosis/HIV at Mulago National Referral Hospital, Uganda, a retrospective cohort study. PLOS Glob Public Health, 2023, vol. 3, no. 7, pp. e0001020. https://doi.org/10.1371/journal.pgph.0001020

12. Bisson G.P., Bastos M., Campbell J.R., Bang D., Brust J.C., Isaakidis P., Lange C., Menzies D., Migliori G.B., Pape J.W., Palmero D., Baghaei P., Tabarsi P., Viiklepp P., Vilbrun S., Walsh J., Marks S.M. Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis. Lancet, 2020, vol. 396, no. 10248, pp. 402-411. https://doi.org/10.1016/S0140-6736(20)31316-7

13. Gandhi N.R., Andrews J.R., Brust J.S., Montreuil R., Weisman D., Heo M., Moll A.P., Friedland G.H., Shah N.S. Risk factors of mortality among patients with MDR- and XDR-tuberculosis in conditions of high HIV prevalence. International Pulmonary Tuberculosis, 2012, vol. 16, no. 1, pp. 90-97. https://doi.org/10.5588/ijted.11.0153

14. Habimana D.S., Ngabonziza J.S., Migambi P., Muzio-Habimana U., Mutembaiire G., Byukusenge F., Habiambere I., Remera E., Mugwaneza P., Mvikarago I.E., Mazarati J.B., Turate I., Nsanzimana S., Dekru T., de Jong K.B. Predictors of mortality from tuberculosis, resistant to rifampicin, among HIV-co-infected patients in Rwanda. Am. J. Trop. Med. Hyg., 2021, vol. 105, no. 1, pp. 47-53. https://doi.org/10.4269/ajtmh.20-1361

15. Oelofse S., Esmail A., Deacon A., Konradi F., Olayanju O., Ngubane N., Howell P., Everitt D., Crook A.M., Mendel K.M., Wills G.H., Olugbosi M., Del Parigi A., San E., Calatroni A., Spigelman M., Dheda K. Pretomanid with bedaquiline and linezolid in drug-resistant tuberculosis: comparison of potential cohorts. International Journal of Pulmonary Tuberculosis, 2021, vol. 25, no. 6, pp. 453-460. https://doi.org/10.5588/ijtld.21.0035

16. Wu Wu, Zhang Wu, Wang Wu, Wei J., Wang V, Duan V, Tian Wu, Ren M, Li Z., Wang Wu, Zhang T, Wu N., Huang H. Bedaquiline and Linezolid improve the results of TB treatment in patients with drug-resistant tuberculosis with HIV: a systematic review and meta-analysis. Pharmacol. Res., 2022, no. 182, pp. 106336. https://doi.org/10.1016/j.phrs.2022.106336

17. Yang Q., Han J., Shen J., Peng X., Zhou L., Yin X. Diagnosis and treatment of tuberculosis in adults with HIV. Medicine (Baltimore), 2022, vol. 101, no. 35, pp. e30405. https://doi.org/10.1097/MD.0000000000030405


Review

For citations:

Sosova N.A., Zadremaylova T.A., Konovalova N.M., Abramchenko A.V., Romanova M.I., Gayda A.I., Samoylova A.G. Treatment Results in Patients with Drug Resistant Tuberculosis (MDR, pre-XDR, XDR) and HIV Infection in Stavropol Region. Tuberculosis and Lung Diseases. 2024;102(3):64-70. (In Russ.) https://doi.org/10.58838/2075-1230-2024-102-3-64-70

Views: 464


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2075-1230 (Print)
ISSN 2542-1506 (Online)

4, Dostoevsky St., 127473, Moscow
National Medical Research Center of Phthisiopulmonology and Infectious
Diseases of the Ministry of Health of the Russian Federation
(Journal of Tuberculosis and Lung Diseases)

 

 

Processing of personal data
supported by NEICON (Elpub lab)